Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (14182)	7/19/2000 11:14:38 PM
From: Bluegreen	Respond to of 17367

George, no one would dare ever underestimate you.<g>

To: Robert K. who wrote (14182)	7/20/2000 12:12:54 AM
From: Bluegreen	Respond to of 17367

Bob, why are they putting these beagles through all of this when all they have to do is ask Stockdoc the big secrets of Genta???? I hope at least you AND GEORGE<g> realize what little ANYONE knows of Gentamycin's mode of action OR ITS FULL CAPABILTIES!!!!! Notice the T word as in Toxicological???? As you know I could go on and on but I think I have made my point>>>>>>>>>>>: Antimicrob Agents Chemother 2000 Jun;44(6):1443-7 Pharmacokinetics of gentamicin C(1), C(1a), and C(2) in beagles after a single intravenous dose. Isoherranen N, Lavy E, Soback S Kimron Veterinary Institute, Beit Dagan, Hebrew University of Jerusalem, Jerusalem, Israel. The pharmacokinetics of gentamicin C(1), C(2), and C(1a) were studied in six beagles after administration of gentamicin at 4 mg/kg of body weight as a single intravenous bolus dose. Plasma concentrations of the gentamicin components were analyzed with a novel high-performance liquid chromatography method capable of identifying and quantifying each of the components. The pharmacokinetic analysis of the plasma concentration-versus-time data was performed using the noncompartmental approach. The results indicated significant differences in the pharmacokinetic characteristics between the gentamicin components C(1), C(1a), and C(2). The mean residence times of gentamicin C(1), C(1a), and C(2) were 81+/-13, 84+/-12, and 79+/-13 min (mean +/- standard deviation), respectively. The half-lives of the respective components were 64+/-12, 66+/-12 and 63+/-12 min. Clearance (CL) of gentamicin C(1), 4.62+/-0.71 ml min(-1) kg(-1), was significantly higher (P = 0.0156) than CL of gentamicin C(1a), 1.81+/-0.26 ml min(-1) kg(-1), and C(2), 1.82+/-0.25 ml min(-1) kg(-1). Similarly, the volume of distribution at steady state (V(ss)) of gentamicin C(1), 0.36+/-0.04 liter kg(-1), was significantly higher (P = 0.0156) than the V(ss) of gentamicin C(1a), 0.14+/-0.01 liter kg(-1), and C(2), 0.15+/-0.02 liter kg(-1). Tissue binding was considered the most likely cause for the difference. The difference may have clinical and toxicological significance.<<<<<<<<<

To: Robert K. who wrote (14182)	7/20/2000 1:20:49 AM
From: aknahow	Read Replies (2) \| Respond to of 17367

Yep, you do click faster! <g> In the context of the LLY find by you also I think the Merck patent is just as important given the fact that these proteins are so far from being approved drugs that bothering to include them somehow seems somehow more significant.

To: Robert K. who wrote (14182)	7/23/2000 1:20:46 AM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

Bob, a double whammy to these poor kids. Both fungus and bacteria!!!!!! Aren't you always talking cancer and Neutropenia???? What is in Neutrophils????? What is MYCOPREX????LOL Hmmmmmmmmmm Now, where would you need Protein C for these cases????>>>>>>>>>Bacteremia and fungemia in hematological and oncological children with neutropenic fever: two-year study in a medical center. Chiu HH, Huang LM, Lee PI, Lee CY Department of Pediatrics, China Medical College Hospital, Taichung, Taiwan, ROC. A retrospective study of bacteremia in children with neutropenic fever admitted to a medical center in Taiwan from Jan. 1994 to Dec. 1995 was performed. There were in total 273 episodes of neutropenic fever during this period, but only 79 pathogens were isolated from blood specimens in 70 episodes. Klebsiella pneumoniae (27.8%), E. coli (10.1%), Staphylococcus aureus (10.1%) and Pseudomonas aeruginosa (7.6%) were the most common pathogens. All the isolates of S. aureus were methicillin sensitive. About half of K. pneumoniae (10/22) was multiple-drug resistant. There were seven infection-related mortality cases, three due to multiple-drug resistant K. pneumoniae, one due to S. aureus, one alpha-hemolytic streptococcus and two fungemia (Cryptococcus neoformans and Fusarium sp.). Vancomycin is not necessary in initial empiric therapy of neutropenic fever, while cefazolin or oxacillin may be included in cases with central venous access device. Antibiotics to cover intestinal flora, especially K. pneumoniae, are paramount in our hospital.<<<<<<<<<<<<